

Table S1. Time to best clinical, biochemical, and radiographic response in individual patients with KSHV-MCD-treated with AZT/VGC

Pt.	RESPONSES						Total # of Cycles	Recurrent or Progressive KSHV-MCD
	Clinical		Biochemical		Radiographic			
	Best	Cycle	Best	Cycle	Best	Cycle		
1	PR	2	SD	NA	CR	4	4	No
2	SFD	2	SD	NA	SD	NA	5	Yes
3*	SFD	1	PR	4	SD	NA	8	Yes
4	CR	3	SD	NA	SD	NA	6	Yes
5	CR	5	PR	10	CR	6	12	No
6 [†]	CR	3	CR	7	CR	22	29	No
7	CR	2	PR	4	SD	NA	11	No
8 [†]	CR	7	CR	10	CR	20	20	No
9	CR	2	PR	2	SD	NA	10	Yes
10 [†]	CR	2	CR	4	CRu	13	13	No
11	SFD	1	SD	NA	SD	NA	8	Yes
12	SD	NA	SD	NA	SD	NA	2	Yes
13	SD	NA	PD	NA	NA	NA	1	Yes
14	PR	2	SD	NA	SD	NA	8	Yes

Pt. = patient number, CR = complete response, CRu = complete response unconfirmed,

SFD = symptom free disease, PR = partial response, SD = stable disease, PD = progressive disease.

Cycle indicates the number of cycles of therapy required to first obtain the best result in each category. For patients who did not achieve at least a PR, time to best response is not applicable (NA).

* Symptom free disease, not classified as complete clinical response due to persistent adenopathy on physical exam

† Patients who completed therapy with AZT/VGC who continue symptom free with 10, 29, and 33 months of follow up

Figure S1. C-Reactive protein on day 1 of cycles 1-4. Serum C-reactive protein (CRP) on patients 1-14. Sample from Day 1 of therapy for cycles 1-4. Cycle 1 value represents baseline (CRP). Patients 5, 6, 8, and 10 (solid symbols) went on to obtain an overall complete response. The lower limit of detection of CRP assay = 0.4 mg/dL.

Figure S1

